Compare DOLE & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOLE | INBX |
|---|---|---|
| Founded | 1851 | 2010 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2021 | 2024 |
| Metric | DOLE | INBX |
|---|---|---|
| Price | $12.97 | $92.38 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $15.00 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 846.1K | 193.5K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $9,172,907,000.00 | $1,300,000.00 |
| Revenue This Year | $4.93 | N/A |
| Revenue Next Year | $1.72 | N/A |
| P/E Ratio | $41.91 | ★ N/A |
| Revenue Growth | 8.23 | ★ 550.00 |
| 52 Week Low | $12.52 | $21.26 |
| 52 Week High | $16.51 | $155.29 |
| Indicator | DOLE | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 31.61 | 59.24 |
| Support Level | $12.52 | $85.94 |
| Resistance Level | $14.56 | $94.52 |
| Average True Range (ATR) | 0.30 | 4.56 |
| MACD | -0.10 | 1.35 |
| Stochastic Oscillator | 14.29 | 98.73 |
Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace. Geographically, the company operates in United States, Ireland, U.K. Spain, Sweden, and Others.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.